INTS - Intensity Therapeutics Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Capital Market Current Price & Safety Score Price: 3.20 USD StockBonds Safety Grade: F Altman Z-Score (Bankruptcy Risk): -10.19 StockBond Score: -3.47 Company Description Intensity Therapeutics Inc is a biotechnology enterprise in the clinical development phase dedicated to discovering advancing and commercializing pharmaceutical treatments for solid tumor cancers The companys primary experimental compound INT2306 is presently undergoing Phase 2 clinical trials This investigational drug targets a range of difficulttotreat solid tumors including those affecting the pancreas colon bile duct as well as squamous cell sarcoma breast and liver cancers Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions A partnership with Merck Sharpe Dohme Corp focuses on evaluating INT2306 in conjunction with Keytruda for advanced pancreatic colon squamous cell and bile duct malignancies Another collaboration with BristolMyers Squibb Company is dedicated to studying INT2306 combined with Yervoy in patients suffering from advanced liver breast and sarcoma cancers Furthermore the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT2306 for women diagnosed with earlystage breast cancer Established in 2012 Intensity Therapeutics maintains its corporate headquarters in Westport Connecticut